MissionIR Articles

Soligenix (NASDAQ: SNGX) is entering a new phase of strategic breadth and influence with the appointment of a seasoned, high-level scientific and policy adviser who brings rarefied experience at the intersection of economics, government and…

In a key development that underscores the advancing clinical trajectory of its lead therapy, Soligenix (NASDAQ: SNGX) announced that the Data Monitoring Committee (“DMC”) overseeing its confirmatory Phase 3 FLASH2 trial of HyBryte(TM) has reported…

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases and biodefense programs, continues to fortify its financial position as it advances toward a series of pivotal and potentially transformational milestones. Following a series…

Soligenix (NASDAQ: SNGX), a clinical-stage biotechnology company focused on rare diseases and public health solutions, has rejuvenated its U.S. Medical Advisory Board for cutaneous T-cell lymphoma (“CTCL”), placing fresh expertise and leadership at the center…

Current vaccines for Ebola and similar filoviruses face a major deployment barrier: Most require storage between 2°C and 8°C throughout transport, making them vulnerable to spoilage when exposed to the high ambient heat common in…

Soligenix (NASDAQ: SNGX) recently announced the closing of a $7.5 million public offering, providing the company with additional capital to advance its pipeline (https://ibn.fm/tCsub). This funding extends Soligenix’s cash runway through the end of 2026,…

Cutaneous T-cell lymphoma (“CTCL”) is a rare but serious form of non-Hodgkin lymphoma that primarily affects the skin. Globally, millions suffer from CTCL, and in Europe, the annual incidence is estimated at 2.9 to 3.9…

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on treatments for rare diseases, announced the expansion of its European Medical Advisory Board to guide its confirmatory Phase 3 trial of HyBryte(TM) in early-stage cutaneous T-cell…

Psoriasis remains a persistent challenge for millions of patients worldwide, and promising new treatments are being closely watched by the medical and investor communities alike. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases…

Soligenix (NASDAQ: SNGX) is continuing to build momentum in its mission to advance HyBryte(TM), a first-in-class treatment for early-stage cutaneous T-cell lymphoma (“CTCL”). That progress is supported by results from its pivotal FLASH trial and its…

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases, announced the appointment of Tomas J. Philipson, PhD as a Strategic Advisor. Dr. Philipson, an expert in U.S.…

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases with unmet medical need. The company’s SGX942 is a novel therapeutic aimed at alleviating oral mucositis, a…

Soligenix (NASDAQ: SNGX) has taken a bold step forward with its latest corporate presentation, offering investors and the broader biotech community a deeper look into the company’s evolving strategy and pipeline (https://ibn.fm/YGu4N). The presentation underscores…

Soligenix (NASDAQ: SNGX) has taken a decisive step forward in the fight against rare diseases, announcing that the FDA has granted orphan drug designation to its investigational therapy dusquetide for the treatment of Behçet’s disease…

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases, announced that President and CEO Christopher J. Schaber, Ph.D., will deliver a corporate presentation at the H.C. Wainwright…

With pivotal phase 3 cancer trial results due in 2026 and multiple fast-tracked therapies advancing through late-stage development, Soligenix (NASDAQ: SNGX) stands at the threshold of potentially transforming treatment paradigms for rare diseases affecting millions…